Evripidis Gavathiotis

List of Publications by Year
in descending order

67 papers	14,789 citations	66315 42 h-index	102432 66 g-index
75 all docs	75 docs citations	75 times ranked	26825 citing authors

#	Article	IF	Citations
1	Physiological and pharmacological modulation of BAX. Trends in Pharmacological Sciences, 2022, 43, 206-220.	4.0	82
2	Co-targeting of BAX and BCL-XL proteins broadly overcomes resistance to apoptosis in cancer. Nature Communications, 2022, 13, 1199.	5.8	66
3	Modulating mitofusins to control mitochondrial function and signaling. Nature Communications, 2022, 13, .	5.8	31
4	Chaperone-mediated autophagy sustains haematopoietic stem-cell function. Nature, 2021, 591, 117-123.	13.7	145
5	Eltrombopag directly inhibits BAX and prevents cell death. Nature Communications, 2021, 12, 1134.	5.8	28
6	Chaperone-mediated autophagy prevents collapse of the neuronal metastable proteome. Cell, 2021, 184, 2696-2714.e25.	13.5	151
7	Chaperone-mediated autophagy: a gatekeeper of neuronal proteostasis. Autophagy, 2021, 17, 2040-2042.	4.3	21
8	Abstract 2986: Conditional reprogramming of primary head and neck tumor cells to establish consistent and diverse cell line models. , 2021, , .		0
9	ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine. Blood Cancer Journal, 2021, 11, 157.	2.8	27
10	Palbociclib Renders Human Papilloma Virusâ€“Negative Head and Neck Squamous Cell Carcinoma Vulnerable to the Senolytic Agent Navitoclax. Molecular Cancer Research, 2021, 19, 862-873.	1.5	17
11	Apoptosis signaling molecules as treatment targets in head and neck squamous cell carcinoma. Laryngoscope, 2020, 130, 2643-2649.	1.1	15
12	Inhibitors of BRAF dimers using an allosteric site. Nature Communications, 2020, 11, 4370.	5.8	48
13	In Response to Regarding: Apoptosis Signaling Molecules as Treatment Targets in Head and Neck Squamous Carcinoma. Laryngoscope, 2020, 130, E458-E459.	1.1	3
14	A small-molecule allosteric inhibitor of BAX protects against doxorubicin-induced cardiomyopathy. Nature Cancer, 2020, 1, 315-328.	5.7	78
15	Small-molecule allosteric inhibitors of BAX. Nature Chemical Biology, 2019, 15, 322-330.	3.9	65
16	Targeting Mitochondrial Structure Sensitizes Acute Myeloid Leukemia to Venetoclax Treatment. Cancer Discovery, 2019, 9, 890-909.	7.7	186
17	Chaperone-Mediated Autophagy Upregulation Rescues Megalin Expression and Localization in Cystinotic Proximal Tubule Cells. Frontiers in Endocrinology, 2019, 10, 21.	1.5	10
18	BCL-2 Protein Family Interaction Analysis by Nuclear Magnetic Resonance Spectroscopy. Methods in Molecular Biology, 2019, 1877, 217-231.	0.4	1

#	Article	IF	Citations
19	Liposomal Permeabilization Assay to Study the Functional Interactions of the BCL-2 Family. Methods in Molecular Biology, 2019, 1877, 111-119.	0.4	3
20	Optimal targeting of BCL-family proteins in head and neck squamous cell carcinoma requires inhibition of both BCL-xL and MCL-1. Oncotarget, 2019, 10, 494-510.	0.8	25
21	Current Insights of BRAF Inhibitors in Cancer. Journal of Medicinal Chemistry, 2018, 61, 5775-5793.	2.9	76
22	MFN2 agonists reverse mitochondrial defects in preclinical models of Charcot-Marie-Tooth disease type 2A. Science, 2018, 360, 336-341.	6.0	187
23	ICBS 2017 in Shanghaiâ€"Illuminating Life with Chemical Innovation. ACS Chemical Biology, 2018, 13, 1111-1122.	1.6	3
24	Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death and Differentiation, 2018, 25, 486-541.	5.0	4,036
25	The RUNX1/IL-34/CSF-1R axis is an autocrinally regulated modulator of resistance to BRAF-V600E inhibition in melanoma. JCI Insight, 2018, 3, .	2.3	29
26	Pulling the BAX trigger for tumor cell death. Oncotarget, 2018, 9, 8204-8205.	0.8	1
27	Cystinosin, the small GTPase Rab11, and the Rab7 effector RILP regulate intracellular trafficking of the chaperone-mediated autophagy receptor LAMP2A. Journal of Biological Chemistry, 2017, 292, 10328-10346.	1.6	62
28	New perspectives for targeting RAF kinase in human cancer. Nature Reviews Cancer, 2017, 17, 676-691.	12.8	285
29	Direct Activation of BAX by BTSA1 Overcomes Apoptosis Resistance in Acute Myeloid Leukemia. Cancer Cell, 2017, 32, 490-505.e10.	7.7	128
30	Progress in targeting the BCL-2 family of proteins. Current Opinion in Chemical Biology, 2017, 39, 133-142.	2.8	82
31	Editorial overview: Chemical genetics and epigenetics. Current Opinion in Chemical Biology, 2017, 39, vi-vii.	2.8	0
32	Pharmacological inhibition of the transcription factor PU.1 in leukemia. Journal of Clinical Investigation, 2017, 127, 4297-4313.	3.9	89
33	Direct Pharmacological Inhibition of the Transcription Factor PU.1 in Acute Myeloid Leukemia. Blood, 2017, 130, 858-858.	0.6	0
34	Self-regulation of BAX-induced cell death. Oncotarget, 2016, 7, 66326-66327.	0.8	10
35	An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling. Cancer Cell, 2016, 30, 485-498.	7.7	130
36	An Autoinhibited Dimeric Form of BAX Regulates the BAX Activation Pathway. Molecular Cell, 2016, 63, 485-497.	4.5	71

#	Article	IF	Citations
37	Correcting mitochondrial fusion by manipulating mitofusin conformations. Nature, 2016, 540, 74-79.	13.7	190
38	Identification of Neutrophil Exocytosis Inhibitors (Nexinhibs), Small Molecule Inhibitors of Neutrophil Exocytosis and Inflammation. Journal of Biological Chemistry, 2016, 291, 25965-25982.	1.6	73
39	Unraveling cell death mysteries. Nature Chemical Biology, 2016, 12, 470-471.	3.9	5
40	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	4.3	4,701
41	Synthetic Antibodies Inhibit Bcl-2-associated X Protein (BAX) through Blockade of the N-terminal Activation Site. Journal of Biological Chemistry, 2016, 291, 89-102.	1.6	25
42	Inhibition of Pro-Apoptotic BAX by a Noncanonical Interaction Mechanism. Molecular Cell, 2015, 57, 873-886.	4.5	116
43	An interconnected hierarchical model of cell death regulation by the BCL-2 family. Nature Cell Biology, 2015, 17, 1270-1281.	4.6	212
44	Design, synthesis and evaluation of marinopyrrole derivatives as selective inhibitors of Mcl-1 binding to pro-apoptotic Bim and dual Mcl-1/Bcl-xL inhibitors. European Journal of Medicinal Chemistry, 2015, 90, 315-331.	2.6	23
45	Marinopyrrole Derivatives with Sulfide Spacers as Selective Disruptors of Mcl-1 Binding to Pro-Apoptotic Protein Bim. Marine Drugs, 2014, 12, 4311-4325.	2.2	9
46	Structure of the eukaryotic translation initiation factor eIF4E in complex with 4EGI-1 reveals an allosteric mechanism for dissociating eIF4G. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E3187-95.	3.3	72
47	Distinct BimBH3 (BimSAHB) Stapled Peptides for Structural and Cellular Studies. ACS Chemical Biology, 2014, 9, 831-837.	1.6	86
48	Structural Perspectives on BCL-2 Family of Proteins. , 2014, , 229-251.		0
49	Multimodal Interaction with BCL-2 Family Proteins Underlies the Proapoptotic Activity of PUMA BH3. Chemistry and Biology, 2013, 20, 888-902.	6.2	61
50	Chemical modulation of chaperone-mediated autophagy by retinoic acid derivatives. Nature Chemical Biology, 2013, 9, 374-382.	3.9	172
51	A Competitive Stapled Peptide Screen Identifies a Selective Small Molecule that Overcomes MCL-1-Dependent Leukemia Cell Survival. Chemistry and Biology, 2012, 19, 1175-1186.	6.2	128
52	Bax regulates primary necrosis through mitochondrial dynamics. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 6566-6571.	3.3	250
53	Direct and selective small-molecule activation of proapoptotic BAX. Nature Chemical Biology, 2012, 8, 639-645.	3.9	160
54	A stapled BIM peptide overcomes apoptotic resistance in hematologic cancers. Journal of Clinical Investigation, 2012, 122, 2018-2031.	3.9	153

#	Article	IF	Citations
55	Tracking BAX once its trigger is pulled. Cell Cycle, 2011, 10, 868-870.	1.3	10
56	BAX unleashed: the biochemical transformation of an inactive cytosolic monomer into a toxic mitochondrial pore. Trends in Biochemical Sciences, 2011, 36, 642-652.	3.7	148
57	Photoreactive Stapled BH3 Peptides to Dissect the BCL-2 Family Interactome. Chemistry and Biology, 2010, 17, 1325-1333.	6.2	45
58	Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 14093-14098.	3.3	296
59	BH3-Triggered Structural Reorganization Drives the Activation of Proapoptotic BAX. Molecular Cell, 2010, 40, 481-492.	4.5	272
60	BAX activation is initiated at a novel interaction site. Nature, 2008, 455, 1076-1081.	13.7	617
61	The Structure of FADD and Its Mode of Interaction with Procaspase-8. Molecular Cell, 2006, 22, 599-610.	4.5	154
62	A Mechanism for Death Receptor Discrimination by Death Adaptors. Journal of Biological Chemistry, 2005, 280, 31974-31980.	1.6	21
63	Drug Recognition and Stabilisation of the Parallel-stranded DNA Quadruplex d(TTAGGGT)4 Containing the Human Telomeric Repeat. Journal of Molecular Biology, 2003, 334, 25-36.	2.0	179
64	Structure of the parallel-stranded DNA quadruplex d(TTAGGGT)4 containing the human telomeric repeat: evidence for A-tetrad formation from NMR and molecular dynamics simulations. Organic and Biomolecular Chemistry, 2003, 1, 1650-1656.	1.5	79
65	Cooperativity in Drugâ^'DNA Recognition:â€‰ A Molecular Dynamics Study. Journal of the American Chemical Society, 2001, 123, 12658-12663.	6.6	150
66	Recognition and Stabilization of Quadruplex DNA by a Potent New Telomerase Inhibitor: NMR Studies of the 2:1 Complex of a Pentacyclic Methylacridinium Cation with d(TTAGGGT)4. Angewandte Chemie - International Edition, 2001, 40, 4749-4751.	7.2	90
67	Sequence-dependent variation in DNA minor groove width dictates orientational preference of Hoechst 33258 in A-tract recognition: solution NMR structure of the 2:1 complex with d(CTTTTGCAAAAG)2. Nucleic Acids Research, 2000, 28, 728-735.	6.5	55